Condiciones de prescripción y financiación de la buprenorfina-Subutex® según la autorización de comercialización en España de 2000 a 2004

Once the conditions for prescribing the medicament have been decided, it is important that the said medicament should be subsidised by the National Health Service. We believe that the commercialization of the buprenorphine-naloxone association should be promoted so as to avoid the possible use of this medicament by intravenous via and the intoxication/overdose deriving therefrom.